BML details 9.9% PMV Pharmaceuticals (PMVP) stake in Schedule 13G/A
Rhea-AI Filing Summary
BML Investment Partners, L.P. filed an amended Schedule 13G reporting its ownership in PMV Pharmaceuticals, Inc.. The fund reports beneficial ownership of 5,292,000 shares of common stock, representing 9.9% of the class as of the event date.
BML has shared voting and dispositive power over all 5,292,000 shares and no sole voting or dispositive power. The filing notes that the securities are not held for the purpose of changing or influencing control of PMV Pharmaceuticals. Braden M. Leonard is deemed an indirect owner through BML Capital Management, LLC, the general partner.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What stake in PMV Pharmaceuticals (PMVP) does BML Investment Partners report?
BML Investment Partners, L.P. reports beneficial ownership of 5,292,000 PMV Pharmaceuticals shares. This position represents 9.9% of the company’s common stock. All of these shares are held with shared voting and shared dispositive power, according to the Schedule 13G/A filing.
What type of SEC filing did BML submit for PMV Pharmaceuticals (PMVP)?
BML Investment Partners filed an amended Schedule 13G/A for PMV Pharmaceuticals. This schedule is used to report ownership by investors who classify their holdings as passive, rather than for the purpose of changing or influencing control of the issuer.
Does BML Investment Partners seek to influence control of PMV Pharmaceuticals (PMVP)?
The filer certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of PMV Pharmaceuticals. The filing also states they are not held in connection with any transaction having that purpose or effect, subject to the noted nomination exception.
Who signs the PMV Pharmaceuticals (PMVP) Schedule 13G/A for BML Investment Partners?
The Schedule 13G/A is signed by Braden M. Leonard on behalf of BML Capital Management, LLC, the general partner of BML Investment Partners, L.P. The filing states Leonard is deemed an indirect owner of the shares held directly by the partnership.
What percentage threshold does BML Investment Partners exceed in PMV Pharmaceuticals (PMVP)?
BML Investment Partners reports owning 9.9% of the outstanding common stock of PMV Pharmaceuticals. This exceeds the 5% reporting threshold that triggers a beneficial ownership disclosure requirement under U.S. securities regulations for Schedule 13D or 13G filings.
Do the reporting persons claim to be a group in the PMV Pharmaceuticals (PMVP) filing?
The comments clarify that although Braden M. Leonard is deemed an indirect owner of shares held by BML Investment Partners, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b)(1) under the Exchange Act.